Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Lung Neoplasms × lazertinib × Clear all

Phase

Status

Unknown 1 Approved for marketing 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Lung Neoplasms 1

Interventions

Cisplatin 39 Carboplatin 26 Gemcitabine 22 Docetaxel 20 Radiotherapy 17 Etoposide 16 Erlotinib Hydrochloride 13 Paclitaxel 12 Drug Therapy 11 Vinorelbine 10 apatinib 8 Gefitinib 8 Blood Specimen Collection 8 endostar protein 7 aumolertinib 7 Thoracic Surgery, Video-Assisted 7 pembrolizumab 6 Vinblastine 6 Pemetrexed 6 sintilimab 5 osimertinib 5 durvalumab 5 anlotinib 5 Surgical Procedures, Operative 5 Fluorodeoxyglucose F18 5 Cyclophosphamide 5 camrelizumab 4 Mitomycin 4 Ifosfamide 4 Hematologic Tests 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05701384 2023-01-27

Lazertinib 160mg in EGFR T790M NSCLC

Samsung Medical Center

Phase 2 Unknown

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡